ABSTRACT
The advance of digital technologies such as big data, cloud computing, and artificial intelligence ushers in the digital era for modern societies. Digital IT innovation plays an increasingly important role in helping supply chains recover from disruptions due to disastrous events like the COVID-19 outbreak. Nevertheless, there is a lack of systematic literature review on the phenomenon. As such an attempt, this paper explores the role of digital technology innovation in enhancing supply chain resilience and answers this question through a literature review and summarizes six dimensions of supply chain resilience, which provides some theoretical guidance for subsequent studies. © 2022 IEEE.
ABSTRACT
Selman (2022) claims that Further on the Returns to Non-traded REITs contains four fundamental errors related to our treatment of non-traded REITs as a group and our choice of benchmark, time period and terminal valuations. In this Reply, we address each of these alleged errors. Non-traded REITs and traded REITs compete in the same market for portfolio assets and thus the two groups of REITs have similar underlying asset risks and gross returns. Comparing non-traded REIT returns to traded REIT returns allows us to isolate the impact of non-traded REITs' high costs and illiquidity on investors after controlling for the risks and gross returns common to non-traded REITs and traded REITs. Non-traded REITs underperformance relative to traded REITs remains when disaggregating NAV REITs from Lifecycle REITS. Moreover, the shortfall we documented for the 64 non-traded REITs operating as of May 1, 2015 grew during the COVID pandemic-from $36.5 billion as of December 31, 2019 to $55.5 billion as of December 31, 2021. We provided our shortfall estimates based both on reported NAVs and secondary market transactions but continue to stress that secondary market transaction prices are most relevant to assessing the returns to investors. © 2022 With Intelligence Ltd.
ABSTRACT
COVID-19 is seriously endangering people's health and has become a global public crisis. The main target of the disease is the respiratory system. Acute respiratory distress syndrome and diffuse alveolar hemorrhage are the main clinical manifestations, which have aroused broad concern. However, SARS-CoV-2 involves multiple organs including the kidney. Acute renal injury caused by the virus is common, but is often underestimated or even overlooked. Acute renal injury is more common in critical patients with COVID-19 and is an independent risk factor for adverse prognosis. The latest research results at home and abroad on COVID-19 complicated with acute renal injury include epidemiology, risk factors, pathogenesis, pathological manifestations, prevention and treatment schemes, which help strengthen clinicians' understanding of acute renal injury, formulate targeted management strategies, and improve the overall prognosis of patients.
ABSTRACT
This study analyzed the effect of Arbidol, a broad-spectrum antiviral compound, on the outcomes of COVID-19 patients. Records of 252 COVID-19 patients were retrospectively analyzed from February 13 to February 29, 2020 in 4 inpatient wards in the Cancer Center, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China. The rate of clinical improvement was significantly greater among patients treated with Arbidol than among those who did not receive Arbidol (86.8% vs. 54.2%). In moderately and severely ill patients, the clinical improvement rates in the Arbidol group were 95.6% and 81.7%, respectively, which was significantly higher than in the no-Arbidol group (66.6% and 53.8%). Among critically ill patients, however, there was no significant difference. The levels of hypersensitive C-reactive protein, lactate dehydrogenase, D-dimer, IL-6, and IL-10 were increased in non-improved patients but declined during treatment in the improved patients. This suggests these mediators are associated with the disease severity and could potentially serve as prognostic markers. Moreover, our data demonstrate that Arbidol is effective in the treatment of COVID-19 patients and may serve as a cost-effective antiviral treatment strategy for patients with moderate to severe COVID-19 symptoms.